Barry Bunin, PhD is Chief Executive Officer of Collaborative Drug Discovery. Barry has overseen over $18 million in business transactions. Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly & Co. Before that he was the founding CEO, President, & CSO of Libraria (now Eidogen-Sertanty). At Libraria, Barry led a team that integrated exhaustive reaction capture (synthetic chemistry) with gene-family wide SAR capture (medicinal chemistry). On the scientific side, he co-authored “Chemoinformatics: Theory, Practice, and Products” (Springer-Verlag), a text that overviews modern chemoinformatics technologies, and “The Combinatorial Index” (Academic Press), a widely used text on high-throughput chemical synthesis. In the lab, Barry did medicinal synthetic chemistry, developing patented new chemotypes for protease inhibition at Axys Pharmaceuticals (now Celera) and RGD mimics to inhibit GP-IIbIIIa at Genentech. Barry received his B.A. from Columbia University and his Ph.D. from UC Berkeley, where he synthesized and tested the initial 1,4-benzodiazepine libraries with Professor Jonathan Ellman.

David N. Cook, PhD is Executive Vice President and Chief Operating Officer of the International AIDS Vaccine Initiative. David has more than 20 years of experience in organizational management and operations in the biotechnology industry. In his role at IAVI, he oversees IAVI’s senior management team and works closely with IAVI’s CEO to put the organization’s long-term strategy for AIDS vaccine development into effect. Over the course of his career, David has held senior positions in such areas as R&D, program management, business development, manufacturing, and clinical and regulatory affairs. Before joining IAVI, he was a consultant for BIO Ventures for Global Health, a nonprofit based in Washington D.C., that seeks to apply the resources and capabilities of the biotechnology industry to develop vaccines, drugs and diagnostics for neglected diseases. In this capacity, he helped BVGH with its business development activities, contributed to the establishment of viable partnerships between companies, NGOs and academic institutions and devised incentives to make participation in global health ventures feasible for commercial enterprises. Immediately before BVGH, David was the CEO and co-founder of Anza Therapeutics, a biotechnology start-up company developing a novel vaccine platform to induce cellular immune responses to fight or prevent diseases such as cancer, hepatitis C, malaria and tuberculosis. Throughout his career, he has led teams to commercialize several biotech products and is an inventor on more than 20 patents. David earned a Ph.D. in chemistry from the University of California, Berkeley, and received undergraduate degrees in American Studies from Harvard College and chemistry from California State University. In 2006, he completed the Stanford Executive Program at Stanford Graduate School of Business.

Jerrold Ellner, MD is Professor and Chief of Infectious Diseases at Boston University School of Medicine and Boston Medical Center. He has studied the immunopathogenesis of TB and TB in HIV through research collaborations in Uganda and Brazil. He has conducted clinical trials of the prevention of treatment of TB as well as the first HIV/AIDS Vaccine Trial in Africa. His research group was the first to show that TB accelerated the course of HIV infection by activating viral replication in latently infected cells. He was one of the principal architects of the Uganda-Case Western Reserve University Research Collaboration, a founding member of the Academic Alliance for AIDS Prevention and Care in Africa which developed the Infectious Diseases Institute at Makerere University, and the founding director of the TB Research Unit at Case Western Reserve University. He currently is PI of an International Collaboration for Infectious Diseases Research (ICIDR) program in Brazil and the TB – Clinical Diagnostics Research Consortium (CDRC). He has authored more than 250 publications on TB and has trained a number of current academic leaders in infectious diseases.

Javier Guzman, MD, MSc has worked in public health policy and practice for 12
 years, specializing in pharmaceutical policy since 2004. He trained
 as a physician, working for several years in planning and implementation
 of primary health care projects in Colombia and subsequently as a Post Graduate Clinical Fellow in Paediatrics at the Royal London Hospital. He worked for the 
London School of Economics and Political Science (LSE) in London and the George Institute for International Health in Sydney and London and has managed
 research projects for the Bill & Melinda Gates Foundation, the World
 Health Organisation, the Wellcome Trust and Product Development
 Partnerships such as the International AIDS Vaccine Initiative and the
 Drugs for Neglected Diseases initiative. As of August 2010, Javier is the Director of Research of Policy Cures, a non-for-profit organisation which provides research, information, decision-making tools and strategic analysis for those involved in the creation of new pharmaceuticals for neglected diseases. Javier is an Honorary Lecturer at the London School of Hygiene and Tropical Medicine (LSHTM) and the University
 of Sydney, and an expert adviser to the European and Developing
 Countries Clinical Trials Partnership and the Global Alliance for
 Vaccines and Immunisation (GAVI). He has an MSc in Health Policy,
 Planning and Financing from LSE and LSHTM and is currently doing an MBA-Executive at the
 Australian Graduate School of Management, Sydney.

Sandeep Kishore, MSc is enrolled in the Weill Cornell Medical College/ Rockefeller/Sloan-Kettering Institute Tri-Institutional MD-PhD program. Sandeep plans a career in global public health as a physician-scientist and public health advocate. His scientific research concerns characterizing gene activation in the parasite responsible for malaria. He has been involved in global health efforts through leading a global student-led campaign against neglected tropical diseases, integrating global health and neglected tropical disease issues into current medical school curricula and successfully advocating for the inclusion of a cholesterol-lowering statin on the World Health Organization’s Model List of Essential Medicines in 2007. In 2009, he served as an invited speaker for the National Academy of Sciences Institute of Medicine Board on Global Health and in 2010, he was nominated as a civil society delegate to the United Nations. He currently serves on the Board of the global NGO Universities Allied for Essential Medicines (UAEM). His health-related work has been featured in the popular press (Scientific Americanand The Scientist) and he is a co-author of a chapter of the forthcoming textbook Global Chronic Disease published by the Oxford University Press. His technical writings in public health have appeared in a broad range of journals including PLoS Medicine, the Nature Reviews series, Clinical Pharmacology & Therapeutics and the Global Forum for Health Research. He is the first The Lancet Prize winner for community service and is a 2008 Paul & Daisy Soros Fellowship for New Americans recipient.

Dennis Liotta, PhD is Professor of Chemistry, Emory University and Director of the Emory Institute for Drug Discovery. He has extensive experience in multidisciplinary research and his laboratory is noted for its collaborative efforts that span a rich spectrum of academic departments. Over the past two and a half decades his research has focused on the discovery and development of novel antiviral, anticancer and antiinflamatory therapeutic agents. He is one of the leaders of the Emory team that developed the antiviral drug, FTC (Emtriva, Emtricitabine), which was approved for the treatment of HIV in July 2003. In addition, he is the inventor of record for several clinically important antivirals, including 3TC (Epivir, Lamivudine), D-D4FC (Reverset, DPC-817), Racivir (racemic FTC) and L-D4FC (Elvucitabine). He is also the lead inventor of MSX-122, a safe, orally available clinical agent for treating cancer and inflammation.

James Love, MPA, MPAff is the Director of Knowledge Ecology International (KEI). He is also the U.S. co-chair of the Trans-Atlantic Consumer Dialogue (TACD) Intellectual Property Policy Committee, chair of Essential Inventions, an advisor to the X-Prize Foundation on a prize for TB diagnostics, and a member of the UNITAID Expert Group on Patent Pools, the MSF Working Group on Intellectual Property, the Stop-TB Partnership working group on new drug development, and the Internet Governance Forum (IGF) Dynamic Coalition on Open Standards. He advises UN agencies, national governments, international and regional intergovernmental organizations and public health NGOs, and is the author of a number of articles and monographs on innovation and intellectual property rights. In 2006, Knowledge Ecology International received a MacArthur Award for Creative and Effective Institutions. James was previously Senior Economist for the Frank Russell Company, a lecturer at Rutgers University, and a researcher on international finance at Princeton University. He holds a Masters of Public Administration from Harvard University’s Kennedy School of Government and a Masters in Public Affairs from Princeton’s Woodrow Wilson School of Public and International Affairs.

Neil McDonnell, Pharm.D. is Deputy Director of Strategy for the Global Health Program of the Bill & Melinda Gates Foundation. He provides strategy and portfolio management advice on a complex and diverse product development pipeline, an array of global health partnerships, and implementation projects in developing countries. He serves as a strategy and portfolio management consultant to individual program teams as they periodically revise their strategies to optimize health impact among the poor. He also is a key strategic linkage between the foundation and senior leadership of leading global health institutions such as UN agencies, the World Bank, GAVI, and the Global Fund. Previously, Neil was chief of staff for the Global Health Program, serving as an advisor to the President of Global Health, overseeing projects originating in the President’s office, facilitating the development and implementation of program-wide strategy, serving as a liaison between the President’s office and foundation administration, and facilitating strategic collaborations between the foundation and leading global health agencies. Before joining the foundation, Neil was vice president of program management at the biotechnology firm ZymoGenetics, overseeing its portfolio of products in development. Prior to that, he spent 9 years in development and commercial operations at Immunex Corporation. He began his career in healthcare as a clinical pharmacist in hematology/oncology and gynecologic oncology at the University of Washington Medical Center. He has product development experience in a variety of therapeutic areas, including medical and surgical hemostasis, oncology, rheumatology, and asthma. Neil received both his Pharm.D. and B.S. Pharm from the University of Washington. He completed a general residency at the University of Washington and Harborview medical centers.

Melinda Moree, PhD is Chief Executive Officer of BIO Ventures for Global Health (BVGH). In her tenure as CEO, she has grown the organization and introduced two significant new programs the Pool for Open Innovation against Neglected Tropical Diseases and Global Health Connect — both of which find the common ground between the goals of global health and the pragmatic needs of companies to bring more biopharmaceutical companies into neglected disease product development. In addition, she has overseen the design of a new “Pay for Success” incentive aimed at increasing the number of companies working on products for neglected diseases. Before joining BVGH, Melinda was the Principal Investigator on the Malaria Policy Project conducted with the Center for Global Development, a member of the team evaluating the International AIDS Vaccine Initiative, and consulted with the Global Alliance for Vaccines and Immunizations. Until early 2007, Melinda was the Director of the Malaria Vaccine Initiative (MVI), a public-private-partnership with a mission to accelerate the development of malaria vaccines and to ensure that they are available and accessible to people in developing countries. She oversaw the growth of the program from $50 million to $300 million and a tripling in staff. Most importantly, a key milestone event — proof of concept (efficacy) in children in Africa — was achieved under her leadership. Prior to joining MVI, Melinda was Manager of Advanced Research at EKOS Corporation and worked in technology transfer at the University of Washington School of Medicine. This work was preceded by an American Association for the Advancement of Science (AAAS) Science and Diplomacy fellowship at the United States Agency for International Development. During the fellowship Melinda began her first work on public private partnerships for the development of technologies and diagnostics for the developing world. She received her PhD in Medical Microbiology from the University of Maryland at Baltimore.

Kevin Outterson, JD works to achieve equitable access without harming innovation incentives, through scholarship that bridges the gap between drug companies and low-income populations. He publishes in both legal journals (Yale Journal of Health Policy, Law & Ethics, Cardozo Law Review, University of Pittsburgh Law Review, Kansas Law Review, American Journal of Law & Medicine) and peer-reviewed medical and health policy journals (Health Affairs, Lancet Infectious Diseases, Environmental Philosophy, Medical Journal of Australia, Journal of Generic Medicines). He has contributed to four recent academic press books edited by leading global scholars. Kevin has testified on pharmaceutical marketing issues before legislative and regulatory bodies in several states, including West Virginia, Massachusetts, Vermont, Maine, New Hampshire and the District of Columbia. At the federal level, he has testified before the US Senate Committee on Health, Education, Labor, & Pensions on global drug pricing, and he has submitted testimony to USTR regarding compulsory licensing of drugs by Brazil and Thailand. Professor Outterson recently served as a speaker on global pharmaceutical intellectual property issues for WIPO and WHO. His other academic work focuses on health disparities, especially racial and linguistic disparities in health. His academic papers can be found at www.ssrn.com. His background is also grounded in the realities of legal practice, as an associate and then a partner in two major U.S. law firms for more than a decade before joining Boston University. His practice included health care transactions domestically, as well as tax and corporate issues for nonprofit health systems and international businesses. He has served as an expert witness in corporate governance issues in state and federal court, defending depositions and testifying at trial.

Jean-Pierre Paccaud, PhD is Business Development Director at the Drugs for Neglected Diseases initiative (DNDi). He is responsible for DNDi’s business development activities, including opportunity identification, contract structure and negotiations, and alliance management. Prior to joining DNDi, he served as Head of Business Development for R&D products at OM Pharma. He also notably founded and led Athelas SA, a startup company active in the field of anti-bacterial drug discovery, until its merger with Merlion Pharmaceuticals. Before taking on entrepreneurial challenges in industry, Jean-Pierre spent more than 15 years in academia, working in immunology, diabetes, and cell biology. Trained as a molecular and cellular biologist, he completed his post-doctoral studies at the University of California at Berkeley, and earned his PhD at the University of Geneva School of Medicine.

Thomas Pogge, PhD is President and Director, Incentives for Global Health, Leitner Professor of Philosophy and International Affairs at Yale University, and Professorial Fellow, ANU Centre for Applied Philosophy and Public Ethics. Having received his Ph.D. in philosophy from Harvard University, Thomas writes and teaches on moral and political philosophy and Kant. His recent publications include John Rawls: His Life and Theory of Justice, Oxford 2007; Freedom from Poverty as a Human Right, edited, Oxford 2007; Global Institutions and Responsibilities, edited with Christian Barry, Blackwell 2005; Real World Justice, edited with Andreas Follesdal, Springer 2005; World Poverty and Human Rights, Polity 2002; and Global Justice, edited, Blackwell 2001. Thomas is editor for social and political philosophy for the Stanford Encyclopedia of Philosophy and a member of the Norwegian Academy of Science. His work was supported, most recently, by the John D. and Catherine T. MacArthur Foundation, the Princeton Institute for Advanced Study, All Souls College (Oxford), the National Institutes of Health, the Australian Research Council, and the BUPA Foundation.

Yves J. Ribeill, PhD is President and Chief Executive Officer of SCYNEXIS, Inc.  Prior to organizing SCYNEXIS, Inc. in 2000, Yves held various positions during a 20-year international pharmaceutical career with Aventis and its predecessor Rhone-Poulenc Rorer. His roles with those companies included Discovery Chemistry Group leader for Anti-Viral Research and later in the Central Nervous System Group in France. He later served as Director of Chemistry for the Anti-Infective Group. He was involved in all phases of the drug discovery and development effort that resulted in the FDA approval of the anti-bacterial Synercid in 1999. Yves is the author of more than 26 publications and 15 patents. He is a member of the Scientific Advisory Committee of the World Health Organization. Yves has a Ph.D. in Chemistry from the University of Montpellier in France.

William Rodriguez, MD is a specialist in global health diagnostics and health care delivery in the developing world. As a member of the Harvard Medical School faculty, he established a research program on global AIDS policy and the use of appropriate diagnostics in resource-limited settings. In 2003 he was asked to assist the South African government with the development and launch of its landmark national HIV treatment program. He left Harvard to become the Chief Medical Officer of the William J. Clinton Foundation, where he helped broker pricing agreements between African and Asian governments, and the major suppliers of HIV drugs and diagnostic tests, such as BD, bioMérieux, Roche, and Cipla. He remained at the Clinton Foundation through 2007, where he worked with the major diagnostics companies, governments, and local clinics to build the market for the available HIV, TB, and malaria diagnostic systems, bringing essential tests to places where they had not previously been accessible. He has served as a consultant to the World Health Organization and the Bill & Melinda Gates Foundation on global HIV and tuberculosis treatment, has been an advisor to more than a dozen national governments, and served as a member of the WHO’s global HIV guidelines committee. In 2008, he co-founded Daktari Diagnostics, and serves as the President and Chief Executive Officer. He is a graduate of Brown University and the Yale University School of Medicine.

Martin John Rogers, PhD is Preclinical Parasite Drug Development Program Officer, Parasitology and International Programs Branch of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health. He received a BSc and PhD in Chemistry from University of Birmingham, U.K. Following Postdoctoral research at Yale University, Department of Molecular Biophysics and Biochemistry, he joined the Laboratory of Parasitic Diseases at NIAID. There, he researched mechanisms of malaria parasite development and protein synthesis. He subsequently joined the antimicrobial group at DuPont Merck Pharmaceutical Company (subsequently DuPont Pharmaceuticals) investigating new antibacterials and antifungals. He rejoined NIAID as a Program Officer, Parasitology and International Programs, and currently manages a large portfolio of grants on parasite drug development, and also the MR4 malaria resources contract.

Una Ryan, OBE, PhD is President and CEO of Diagnostics for All, a non-profit focused on low cost, easy to use diagnostics for the developing world. 
She was formerly President and CEO of Waltham Technologies, Inc and before this she was president and CEO of AVANT Immunotherapeutics, Inc. a publicly traded (NASDAQ) biopharmaceutical company developing vaccines. She is also Research Professor of Medicine at Boston University School of Medicine and serves on its Board of Visitors. She serves on the board of AMRI , IQuum, Rhapsody Biologics, the Business Advisory Board of BIO Ventures for Global Health, the Business Advisory Board of Genocea, Inc., the Advisory Board of Phacilitate Vaccine Forum and the UMASS High Technology Executive Council. She is a member of the Massachusetts Life Sciences Collaborative Leadership Council, Goddard Council on science, technology, engineering and mathematics education and the Massachusetts Climate Change and Green Economy Council.
 Una holds a Ph.D. in Cellular and Molecular Biology from Cambridge University and BS degrees in Zoology, Microbiology and Chemistry from Bristol University. In 2009 she received an Honorary Doctor of Science degree from Bristol University and the Cartier Women’s Initiative Award. In 2007, she received the Albert Einstein Award for outstanding achievement in the life sciences. In 2002 Her Majesty Queen Elizabeth II awarded her the Order of the British Empire (OBE) for services to the research, development and promotion of biotechnology.

Jonathon Simon, MPH, DSc is the Chair of the Department of International Health, Director of the Center for Global Health and Development, and Professor of International Health at the BUSPH. He received his Bachelor of Science from the University of California at Berkeley in Conservation and Resource Studies. His MPH is also from UC Berkeley. Jonathon received his Doctorate of Science from the Harvard University School of Public Health, having completed dissertation research on the changing demography of Dhaka, Bangladesh. He has been involved in applied child health research activities for 20 years, working in more than twenty developing countries. Before joining Boston University, Jonathon was a Fellow of the Harvard Institute for International Development, where he was Principal Investigator for a large multi-country applied research project. During his tenure at HIID, he was resident in Pakistan for two years as the regional advisor. Jonathon has had extensive experience working in Africa, particularly on issues including child survival, infectious diseases, and capacity strengthening. He has recently been involved in a new area of research, evaluating the economic impact of the HIV/AIDS epidemic on sectors of the African economy.

Denice Spero, PhD has an extensive background in pharmaceutical Research and Development at Boehringer Ingelheim Pharmaceuticals, Inc. Most recently, as Vice President of drug discovery support, she was responsible for establishing and leading the discovery organization’s science in drug metabolism and pharmacokinetics (DMPK), pharmaceutics, and general pharmacology for the therapeutic areas Immunology and Inflammation and Cardiovascular Diseases. In this capacity she and her team established over 30 assays to evaluate drug candidates for optimal safety and DMPK characteristics. She also led a team of scientists which successfully placed three drugs into clinical development for Multiple Sclerosis and Rheumatoid Arthritis. Dr. Spero was highly active in the Diversity and Inclusion initiatives at Boehringer Ingelheim and was a women’s leadership mentor and diversity spokesperson to R&D. She co-founded Developing World Cures, Inc. (DWC) and functioned as its President and member of the board through 2009. DWC was established to discover and develop new therapeutics for the treatment of neglected diseases with a focus on diarrheal diseases and dengue virus. Dr. Spero is now the co-Director of the Institute for Immunology and Informatics and holds a Research Professor position at the University of Rhode Island. The Institute for Immunology and Informatics was founded with a 13M dollar U-19 grant to accelerate vaccine discovery in the areas of infectious diseases and biodefense using state of the art bioinformatics tools. She holds over 60 publications and patents and has given numerous invited lectures in the fields of synthetic chemistry, medicinal chemistry and drug metabolism and pharmacokinetics. Dr. Spero holds a B.A. in chemistry and biology, Summa Cum Laude and Phi Beta Kappa, from Wheaton College, an M.S. in organic chemistry from the Massachusetts Institute of Technology, and a Ph.D. in organic chemistry from Brown University. She did post-doctoral research at Harvard University in the laboratory of Professor Y. Kishi.

Ashley Stevens, D. Phil. (Oxon), CLP is Special Assistant to the VP of Research at Boston University, where he has been tasked with exploring the faculty’s interest in launching a university-wide academic program focused on the role of intellectual property and the evolution of models for the translation of ideas and knowledge into economic development. Previously, he spent 15 years as Director and then Executive Director, Technology Transfer in the Office of Technology Development at Boston University. He is also Senior Research Associate in the Institute for Technology Entrepreneurship and Commercialization in Boston University’s School of Management, where he teaches two graduate-level, inter-disciplinary courses on Technology Commercialization. Before joining Boston University, he was Director of the Office of Technology Transfer at the Dana-Farber Cancer Institute, a teaching affiliate of the Harvard Medical School. Since he joined Boston University, the Office of Technology Development has spun out over 50 companies based on the University’s research, a number of which have raised substantial amounts of capital, and the University’s licensing income climbed steadily. Prior to entering the technology transfer profession, he worked in the biotechnology industry for nearly ten years. He was a co-founder of Kytogenics, Inc., of which he is still a Director, was co-founder and General Manager of Genmap, Inc., and was Vice President of Business Development for BioTechnica International. He started his career with The Procter & Gamble Company, where he held a number of positions in sales, marketing, strategic planning and acquisitions. Ashley publishes and lectures frequently on many aspects of technology transfer, including the Bayh-Dole Act, the economic impact of technology transfer and its role in economic development, the contribution of academia to the discovery of new drugs and vaccines, the role of technology transfer in global health and technology valuation. He was the recipient of the Bayh-Dole Award at Association of University Technology Managers 2007 Annual Meeting and became President of AUTM in March 2010. He is also active in the Licensing Executives Society and the Massachusetts Biotechnology Council. Ashley holds a Bachelor of Arts in Natural Sciences, a Master of Arts and a Doctor of Philosophy in Physical Chemistry from Oxford University. He is a Certified Licensing Professional.

Els Torreele, PhD is the Project Director of the Access to Essential Medicines Initiative at the Open Society Institute (OSI), based in New York. Els graduated as a Bio-Engineer and obtained a PhD in Applied Biological Sciences from the Free University Brussels (VUB). During her years as R&D coordinator at the Flanders Interuniversity Institute for Biotechnology, she became increasingly interested in policy issues including research agenda setting, patenting of research findings, and the commercialization of (public) biotechnology research. She joined the Médecins Sans Frontières (MSF/Doctors Without Borders) Access to Essential Medicines Campaign in its pioneering years as coordinator and chair of the Drugs for Neglected Diseases Working Group. In 2003, she joined the Drugs for Neglected Diseasess initiative (DNDi) as a founding team member, and was responsible for the set-up and management of several drug development projects including preclinical drug development, clinical research activities in disease-endemic areas (sub-Saharan Africa), capacity strengthening for research in endemic countries, and international advocacy for increased R&D for neglected diseases. Els joined OSI‘s Public Health Program in September 2009, eager to return to broader Access to Essential Medicines issues, combining her interests for global health and innovation with civil society strengthening and advocacy to influence policy.

George M. Whitesides, PhD: Woodford L. and Ann A. Flowers University Professor. Born, 1939, Louisville, KY. A.B., Harvard, 1960. Ph.D., 1964, California Institute of Technology (with J.D. Roberts). Faculty: Massachusetts Institute of Technology, 1963 to 1982; Harvard University, 1982-present.
Awards: Alfred P. Sloan Fellowship (1968) American Chemical Society (ACS) Award in Pure Chemistry (1975). James Flack Norris Award (ACS, New England Section) (1994). Arthur C. Cope Award (ACS) (1995). Defense Advanced Research Projects Agency Award for Significant Technical Achievement (1996). Madison Marshall Award (ACS) (1996). National Medal of Science (1998). Sierra Nevada Distinguished Chemist Award (Sierra Nevada Section of the ACS) (1999). The Wallac Oy Innovation Award in High Throughput Screening (Society for Biomolecular Screening) (1999). Award for Excellence in Surface Science (Surfaces in Biomaterials Foundation) (1999). Von Hippel Award (Materials Research Society) (2000). World Technology Award for Materials from the World Technology Network (2001). Doctorate Honoris Causa, University of Twente (The Netherlands) (2001). Small Times Magazine’s Researcher of the Year Award (2002). Pittsburgh Analytical Chemistry Award (Society for Analytical Chemists of Pittsburgh) (2003). Kyoto Prize (2003). Paracelsus Prize (Swiss Chemical Society) (2004). Ralph and Helen Oesper Award (Cincinnati Section of ACS) (2004). Jacob Heskel Gabbay Award in Biotechnology and Medicine (2004). 2004 Dickson Prize in Science (Carnegie Mellon University) (2005). Dan David Prize (Dan David Foundation) (2005). Emanuel Merck Lecture Prize, (Technische Universität Darmstadt/Merck) (2005). Linus Pauling Medal Award (Portland, Puget Sound and Oregon Sections of ACS) 2005. Welch Award (The Welch Foundation) (2005), U.A.A. Dhirubhai Ambani Lifetime Achievement Award (Indian National Science Academy), Priestley Medal (ACS) (2007), August-Wilhelm-von Hoffman -Vorlesung (German Chemical Society) (2007), Wheland Medal (University of Chicago) (2008), Prince of Asturias Award (2008), Benjamin Franklin Medal in Chemistry (Franklin Foundation) (2009), Popular Mechanics Breakthrough Award (2009), Dreyfus Prize in the Chemical Sciences (2009).
Memberships and Fellowships: American Academy of Arts and Sciences, National Academy of Sciences, National Academy of Engineering, American Philosophical Society, Fellow of the American Association for the Advancement of Science, Fellow of the Institute of Physics, New York Academy of Sciences, World Technology Network, Honorary Member of the Materials Research Society in India, Royal Netherlands Academy of Arts and Sciences, Foreign Fellow of the Indian National Science Academy, and Honorary Fellow of the Royal Society of Chemistry (UK).



MeND2010: 10-11 September, 2010, Boston University
Download the program (PDF)Download the flyer to share (PDF)Contact us